TD Cowen analyst Phil Nadeau maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report) today. The company’s shares closed last ...

In recent trading, Syndax Pharmaceuticals Inc (SNDX) stock price has shown some volatility, fluctuating -27.42% over the last five trades and -20.41% over the past 30 trades. This represents a notable ...

Syndax Pharmaceuticals (SNDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kelly ...

The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals’ Revuforj (revumenib). Revuforj is the first ...

On Thursday, Syndax Pharmaceuticals Inc (SNDX) stock saw a modest uptick, ending the day at $16.79 which represents a slight increase of $0.16 or 0.96% from the prior close of $16.63. The stock opened ...

Syndax Pharmaceuticals Inc (SNDX) reports robust financials and strategic milestones, including FDA approvals and a ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Below is a chart showing NUE's trailing twelve month trading history, with the $170 strike highlighted in orange: And Syndax Pharmaceuticals Inc (Symbol: SNDX) saw options trading volume of 4,800 ...

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $0.73 per share a year ago.

Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price target boosted by HC Wainwright from $45.00 to $47.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The ...